WeissJ, HaefeliWE: Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents, 2013; 41:484–487.
2.
XingY, YanJ, NiuY: PXR: a center of transcriptional regulation in cancer. Acta Pharm Sin B, 2020; 10:197–206.
3.
YanM, WangC, HeB, et al.: Aurora-A kinase: A potent oncogene and target for cancer therapy. Med Res Rev, 2016; 36:1036–1079.
4.
LuB-W, XieL-K: Potential applications of artemisinins in ocular diseases. Int J Ophthalmol, 2019; 12:1793–1800.
5.
LiC, FengX, WenX, et al.: A pilot clinical study of intravitreal injection of artesunate for ocular neovascularization. J Ocul Pharmacol Ther, 2019; 35:283–290.
6.
WangX, SongW, ZhangF, HuangR: Dihydroartemisinin inhibits TGF-β-induced fibrosis in human tenon fibroblasts via inducing autophagy. Drug Des Devel Ther, 2021; 15:973–981.
7.
DalbethN, LauterioTJ, WolfeHR: Mechanism of action of colchicine in the treatment of gout. Clin Ther, 2014; 36:1465–1479.
8.
LiantiniotiG, ArgyrisAA, ProtogerouAD, VlachoyiannopoulosP: The role of colchicine in the treatment of autoinflammatory diseases. Curr Pharm Des, 2018; 24:690–694.
9.
ErgulM, Bakar-AtesF: Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro, 2021; 73:105138.
10.
LötscherM, KaisslingB, BiberJ, MurerH, LeviM: Role of microtubules in the rapid regulation of renal phosphate transport in response to acute alterations in dietary phosphate content. J Clin Invest, 1997; 99:1302–1312.
11.
DousaTP, DuarteCG, KnoxFG: Effect of colchicine on urinary phosphate and regulation by parathyroid hormone. Am J Physiol, 1976; 231:61–65.
12.
Santos-GallegoCG, Vargas-DelgadoAP, Requena-IbanezJA, et al.: EMPA-TROPISM (ATRU-4) Investigators. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol, 2021; 77:243–255.
13.
AnkerSD, ButlerJ, FilippatosG, et al.: EMPEROR-preserved trial investigators. empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 2021; 385:1451–1461.
14.
FernandesGC, FernandesA, CardosoR, et al.: Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm, 2021; 18:1098–1105.
15.
UthmanL, BaartscheerA, BleijlevensB, et al.: Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na +/H + exchanger, lowering of cytosolic Na + and vasodilation. Diabetologia, 2018; 61:722–726.
16.
SchietzelS, BallyL, CereghettiG, et al.: Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ Open, 2022; 12:e059073.
17.
SubramanianA, NarayanR, CorselloSM, et al.: A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell, 2017; 171:1437–1452.e17.
18.
BlascoV, PintoFM, Fernández-AtuchaA, González-RavinaC, Fernández-SánchezM, CandenasL: Female infertility is associated with an altered expression of the neurokinin B/neurokinin B receptor and kisspeptin/kisspeptin receptor systems in ovarian granulosa and cumulus cells.. Fertil Steril, 2020; 114:869–878.
19.
BlascoV, PintoFM, González-RavinaC, Santamaría-LópezE, CandenasL, Fernández-SánchezM: Tachykinins and kisspeptins in the regulation of human male fertility. J Clin Med, 2019; 9:113.
20.
EndoN, TanakaT: Effects of senktide, a neurokinin 3 receptor agonist, on luteinizing hormone secretion and follicular development in anestrous Shiba goats: a pilot study. BMC Res Notes, 2014; 7:773.
21.
ChenZ, LiuM, HuJH, GaoY, DengC, JiangMH: Substance P restores spermatogenesis in busulfan-treated mice: a new strategy for male infertility therapy. Biomed Pharmacother, 2021; 133:110868.
22.
PintadoOC, PintoFM, PennefatherJN, et al.: A role for tachykinins in female mouse and rat reproductive function. Biol Reprod, 2003; 69:940–946.
23.
WilsonD, HebeckerB, MoyesDL, et al.: Clotrimazole dampens vaginal inflammation and neutrophil infiltration in response to Candida albicans infection. Antimicrob Agents Chemother, 2013; 57:5178–5180.
24.
WangZ, XuF, HuJ, et al.: Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity. J Immunother Cancer, 2021; 9:e002155.
25.
SenS, KaminiskiR, DeshmaneS, et al.: Role of hexokinase-1 in the survival of HIV-1-infected macrophages. Cell Cycle, 2015; 14:980–989.
26.
HandleyR, StewartAS: Mysoline; a new drug in the treatment of epilepsy. Lancet, 1952; 1:742–744.
27.
DegterevA, OfengeimD, YuanJ: Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA, 2019; 116:9714–9722.
28.
RiebelingT, JamalK, WilsonR, et al.: Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ, 2021; 28:1610–1626.
29.
StresemannC, LykoF: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer, 2008; 123:8–13.
30.
CarretteLLG, BlumR, MaW, KelleherRJ, LeeJT: Tsix-Mecp2 female mouse model for Rett syndrome reveals that low-level MECP2 expression extends life and improves neuromotor function. Proc Natl Acad Sci USA, 2018; 115:8185–8190.
31.
CarretteLLG, WangCY, WeiC, et al.: A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders. Proc Natl Acad Sci USA, 2018; 115:E668–E675.
32.
MalhotraN, GuptaR, KumarP: Pharmacological relevance of CDK inhibitors in Alzheimer's disease. Neurochem Int, 2021; 148:105115.
33.
SkoviraJW, WuJ, MatyasJJ, et al.: Cell cycle inhibition reduces inflammatory responses, neuronal loss, and cognitive deficits induced by hypobaria exposure following traumatic brain injury. J Neuroinflammation, 2016; 13:299.
34.
OsugaH, OsugaS, WangF, et al.: Cyclin-dependent kinases as a therapeutic target for stroke. Proc Natl Acad Sci USA, 2000; 97:10254–10259.
35.
ArsenijevicY: Cell cycle proteins and retinal degeneration: evidences of new potential therapeutic targets. Adv Exp Med Biol, 2016; 854:371–377.
36.
ChongQY, KokZH, BuiNL, et al.: A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib. Pharmacol Res, 2020; 156:104686.
37.
Martínez-ChávezA, LoosNHC, LebreMC, et al.: ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacol Res, 2021; 178:105954.
38.
De PaloG, VeronesiU, MarubiniE, et al.: Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. J Cell Biochem Suppl, 1995; 22:11–17.
39.
MataNL, LichterJB, VogelR, HanY, BuiTV, SingermanLJ: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina, 2013; 33:498–507.
40.
GarićD, DumutDC, ShahJ, De SanctisJB, RadziochD: The role of essential fatty acids in cystic fibrosis and normalizing effect of fenretinide. Cell Mol Life Sci, 2020; 7:4255–4267.
Brennan-JonesCG, McMahenC, Van DalenEC: Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer. Int J Audiol, 2019; 58:181–184.
KruegerRE, MayerGD: Tilorone hydrochloride: an orally active antiviral agent. Science, 1970; 169:1213–1214.
45.
MayerGD, KruegerRF: Tilorone hydrochloride: mode of action. Science, 1970; 169:1214–1215.
46.
VignauxPA, MineraliE, LaneTR, et al.: The antiviral drug tilorone is a potent and selective inhibitor of acetylcholinesterase. Chem Res Toxicol, 2021; 34:1296–1307.
47.
MorahanPS, MunsonJA, BairdLG, KaplanAM, RegelsonW: Antitumor action of pyran copolymer and tilorone against Lewis lung carcinoma and B-16 melanoma. Cancer Res, 1974; 34:506–511.
48.
IacovelliNA, TorrenteY, CiuffredaA, et al.: Topical treatment of radiation-induced dermatitis: current issues and potential solutions. Drugs Context, 2020; 9:2020-4-7.
49.
CorreI, GuillonneauM, ParisF: Membrane signaling induced by high doses of ionizing radiation in the endothelial compartment. Relevance in radiation toxicity. Int J Mol Sci, 2013; 14:22678–22696.
50.
JaddoaE, MasaniaJ, MasieroE, et al.: Effect of antidepressant drugs on the brain sphingolipid system. J Psychopharmacol, 2020; 34:716–725.
